CB
CBUS.US Cibus Global LLC
- Market cap
- USD 86.4M
- P/E
- -
- P/B
- 5.58x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CBUS.US undervalued?
Graham numberThe Graham number of Cibus Global LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cibus Global LLC fundamental analysis
No fundamental analysis for Cibus Global LLC yet.
Cibus Global LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cibus Global LLC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The co…
Full company profileCibus Global LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cibus Global LLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 399K | 508K | 236K | 7.30M | 23.9M | 26.0M | 157K | 1.82M | 4.26M | 3.64M | 4.63M |
| Gross Profit | 199K | -43.0K | -845K | -1.98M | -11.3M | -2.57M | 157K | 1.42M | -2.60M | -2.28M | 1.49M |
| Operating Income | -12.1M | -25.8M | -28.1M | -39.7M | -43.8M | -29.3M | -22.4M | -319M | -77.0M | -67.5M | -50.1M |
| EBITDA | -11.7M | -25.2M | -25.6M | -36.5M | -41.5M | -25.4M | -20.8M | -315M | -242M | -90.8M | -44.6M |
| Net Income | -12.1M | -26.0M | -27.9M | -39.6M | -44.8M | -29.2M | -16.9M | -268M | -251M | -127M | -87.1M |
| EPS | -1.14 | -2.81 | -2.27 | -3.02 | -3.31 | -2.52 | -1.46 | -26 | -11 | -2.78 | -1.13 |
| Balance Sheet | |||||||||||
| Total Assets | 16.6M | 72.2M | 119M | 88.1M | 63.3M | 37.2M | 22.4M | 544M | 350M | 305M | 301M |
| Total Liabilities | 3.50M | 14.7M | 25.4M | 25.6M | 26.5M | 23.1M | 15.2M | 206M | 252M | 283M | 307M |
| Shareholders' Equity | 13.1M | 57.5M | 93.4M | 62.5M | 36.9M | 14.1M | 7.23M | 338M | 97.8M | 21.8M | -5.67M |
| Cash & Short-term Investments | 5.03M | 56.7M | 93.8M | 58.6M | 29.0M | 13.8M | 3.43M | 32.7M | 14.4M | 9.92M | 10.7M |
| Total Debt | - | 10.1M | 18.5M | 18.6M | 19.8M | 17.9M | 13.5M | 24.6M | 36.3M | 268M | 31.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.24M | -12.8M | -20.3M | -32.0M | -43.7M | -18.8M | -19.4M | -46.2M | -58.0M | -50.6M | -40.3M |
| Capital Expenditure | 10.4M | 779K | 1.85M | 2.97M | 1.79M | 497K | 1.52M | 4.32M | 808K | 578K | 209K |
| Free Cash Flow | -19.7M | -13.6M | -22.1M | -34.9M | -45.5M | -19.3M | -20.9M | -50.5M | -58.9M | -51.2M | -40.4M |
| Ratios | |||||||||||
| ROE | -92.1% | -45.2% | -29.9% | -63.4% | -121.6% | -206.6% | -233.5% | -79.1% | -257.0% | -582.2% | - |
| ROA | -72.7% | -36.0% | -23.5% | -45.0% | -70.8% | -78.5% | -75.3% | -49.2% | -71.8% | -41.7% | -28.9% |
| Net Profit Margin | -3,029.1% | -5,114.2% | -11,820.8% | -542.9% | -188.0% | -112.4% | -10,758.6% | -14,729.1% | -5,898.4% | -3,492.3% | -1,879.4% |
| Debt to Equity | - | 0.18x | 0.20x | 0.30x | 0.54x | 1.26x | 1.87x | 0.07x | 0.37x | 12.28x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cibus Global LLC dividends
Cibus Global LLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Jun 1, 2023.
Who owns Cibus Global LLC
- Insiders 26.10%
- Institutions 29.83%
- Public & others 44.07%
- Shares outstanding 76.4M
- Free float 57.2M
Top funds holding CBUS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.40M | 4.45% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.60M | 2.10% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 979K | 1.28% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 849K | 1.11% | 0.00% | Aug 2026 |
| Fidelity Blue Chip Growth | 716K | 0.94% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 255K | 0.33% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 182K | 0.24% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 177K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Series Blue Chip Growth | 134K | 0.18% | 0.00% | Aug 2026 |
| Fidelity Blue Chip Growth K6 | 121K | 0.16% | -0.24% | Sep 2026 |
| Fidelity Total Market Index | 101K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 77.9K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 50.9K | 0.07% | 0.00% | Aug 2026 |
| Global X AgTech & Food Innovation ETF | 36.1K | 0.05% | 0.00% | Oct 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 30.7K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 29.5K | 0.04% | 0.00% | Sep 2026 |
| Global X AgTech & Food Innovt ETF USDAcc | 18.1K | 0.02% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 16.9K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 13.2K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Blue Chip Grth Multi Ass Base O | 4.70K | 0.01% | 0.00% | Jun 2026 |
Top institutions holding CBUS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 11.4M | 14.98% | +0.21% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.30M | 3.01% | +8.57% | Jun 2026 |
| United Capital Financial Advisers Inc | 576K | 0.75% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 528K | 0.69% | +9.39% | Jun 2026 |
| BlackRock Inc | 493K | 0.64% | +18.70% | Jun 2026 |
| Prescott Group Capital Management LLC | 328K | 0.43% | 0.00% | Jun 2026 |
| Squarepoint Ops LLC | 312K | 0.41% | +0.08% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 310K | 0.41% | +20.14% | Jun 2026 |
| CI Private Wealth LLC | 165K | 0.22% | 0.00% | Jun 2026 |
| State Street Corp | 157K | 0.21% | 0.00% | Jun 2026 |
| LPL Financial Corp | 142K | 0.19% | +35.27% | Jun 2026 |
| Renaissance Technologies Corp | 133K | 0.17% | +33.97% | Jun 2026 |
| Northern Trust Corp | 131K | 0.17% | +25.04% | Jun 2026 |
| Capital Advisor Network LLC | 130K | 0.17% | +67.44% | Jun 2026 |
| Lynx Capital Group LTD | 74.0K | 0.10% | +37.04% | Jun 2026 |
| Summit Trail Advisors, LLC | 69.1K | 0.09% | 0.00% | Jun 2026 |
| Citigroup Inc | 63.6K | 0.08% | +378.90% | Jun 2026 |
| Moneta Group Investment Advisors Inc | 59.5K | 0.08% | 0.00% | Jun 2026 |
| Millennium Management LLC | 59.0K | 0.08% | -86.12% | Jun 2026 |
| Bank of Oklahoma National Association | 50.0K | 0.07% | 0.00% | Jun 2026 |
Cibus Global LLC company profile
- Company name
- Cibus Global LLC
- Ticker
- CBUS.US
- Exchange
- USA Stocks
- Listed since
- Jun 1, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 118
- Fiscal year end
- December
- Address
- 6455 Nancy Ridge Drive, San Diego, CA, United States, 92121
- Phone
- 858 450 0008
- Website
- cibus.com
About Cibus Global LLC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Cibus Global LLC management
8- Mr. Craig WichnerChief Executive Officer · born 1970
- Dr. Peter R. Beetham B.Sc., Ph.D.Co-Founder, President & COO · born 1963
- Dr. Gregory F. Gocal Ph.D.Co-Founder, Chief Scientific Officer & Executive VP · born 1969
- Mr. Rory Balfour Riggs M.B.A.Co-Founder & Director · born 1953
- Mr. Jason Stokes Esq., J.D.Chief Administrative Officer, General Counsel & Corporate Secretary · born 1971
- Mr. Cornelis Broos M.Sc.Chief Financial Officer · born 1972
- Ms. Rosa Cheuk Kim J.D.Senior Vice President of Legal
- Dr. Noel Sauer Ph.D.Senior Vice President of Research · born 1967